{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:04Z","timestamp":1790775124578,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00259-016-3445-y","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:36:21Z","timestamp":1467074181000},"page":"2183-2189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Striatal hypometabolism in premanifest and manifest Huntington\u2019s disease patients"],"prefix":"10.1007","volume":"43","author":[{"given":"Diego Alfonso","family":"L\u00f3pez-Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valle","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00fcl","family":"Mart\u00ednez-Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Sampedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Andrea","family":"Lozano-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"G\u00f3mez-Anson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Carri\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"key":"3445_CR1","doi-asserted-by":"crossref","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov Disord. 1996;11(2):136\u201342.","DOI":"10.1002\/mds.870110204"},{"key":"3445_CR2","doi-asserted-by":"crossref","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72(6):971\u201383.","DOI":"10.1016\/0092-8674(93)90585-E"},{"issue":"8","key":"3445_CR3","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","volume":"96","author":"E Scherzinger","year":"1999","unstructured":"Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington\u2019s disease pathology. Proc Natl Acad Sci U S A. 1999;96(8):4604\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3445_CR4","first-page":"215","volume":"47","author":"A Ciarmiello","year":"2006","unstructured":"Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington\u2019s disease. J Nucl Med. 2006;47(2):215\u201322.","journal-title":"J Nucl Med"},{"issue":"9","key":"3445_CR5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00415-012-6428-3","volume":"259","author":"M Politis","year":"2012","unstructured":"Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol. 2012;259(9):1769\u201380.","journal-title":"J Neurol"},{"issue":"5","key":"3445_CR6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/brain\/113.5.1405","volume":"113","author":"T Kuwert","year":"1990","unstructured":"Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington\u2019s disease. Brain. 1990;113(5):1405\u201323.","journal-title":"Brain"},{"issue":"1","key":"3445_CR7","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","volume":"122","author":"TC Andrews","year":"1999","unstructured":"Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, et al. Huntington\u2019s disease progression. PET and clinical observations. Brain. 1999;122(1):2353\u201363.","journal-title":"Brain"},{"issue":"2","key":"3445_CR8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.expneurol.2008.12.015","volume":"216","author":"JS Paulsen","year":"2009","unstructured":"Paulsen JS. Functional imaging in Huntington\u2019s disease. Exp Neurol. 2009;216(2):272\u20137.","journal-title":"Exp Neurol"},{"issue":"5","key":"3445_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.410120504","volume":"12","author":"DE Kuhl","year":"1982","unstructured":"Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington\u2019s disease determined by 18FDG and computed tomographic scan. Ann Neurol. 1982;12(5):425\u201334.","journal-title":"Ann Neurol"},{"issue":"3","key":"3445_CR10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ana.410200305","volume":"20","author":"AB Young","year":"1986","unstructured":"Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, et al. PET scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol. 1986;20(3):296\u2013303.","journal-title":"Ann Neurol"},{"issue":"7","key":"3445_CR11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.36.7.888","volume":"36","author":"MR Hayden","year":"1986","unstructured":"Hayden MR, Martin WR, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, et al. Positron emission tomography in the early diagnosis of Huntington\u2019s disease. Neurology. 1986;36(7):888\u201394.","journal-title":"Neurology"},{"issue":"3","key":"3445_CR12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/archneur.1987.00520150010010","volume":"44","author":"AB Young","year":"1987","unstructured":"Young AB, Penney JB, Starosta-Rubinstein S, Markel D, Berent S, Rothley J, et al. Normal caudate glucose metabolism in persons at risk for Huntington\u2019s disease. Arch Neurol. 1987;44(3):254\u20137.","journal-title":"Arch Neurol"},{"issue":"9","key":"3445_CR13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.37.9.1441","volume":"37","author":"MR Hayden","year":"1987","unstructured":"Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington\u2019s disease. Neurology. 1987;37(9):1441\u20137.","journal-title":"Neurology"},{"issue":"7","key":"3445_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM198702123160701","volume":"316","author":"JC Mazziotta","year":"1987","unstructured":"Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington\u2019s disease. N Engl J Med. 1987;316(7):357\u201362.","journal-title":"N Engl J Med"},{"issue":"5","key":"3445_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/00004728-199209000-00022","volume":"16","author":"T Kuwert","year":"1992","unstructured":"Kuwert T, Ganslandt T, Jansen P, J\u00fclicher F, Lange H, Herzog H, et al. Influence of size of regions of interest on PET evaluation of caudate glucose consumption. J Comput Assist Tomogr. 1992;16(5):789\u201394.","journal-title":"J Comput Assist Tomogr"},{"issue":"6","key":"3445_CR16","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain. 1996;119(6):2085\u201395.","journal-title":"Brain"},{"issue":"6","key":"3445_CR17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00259-012-2114-z","volume":"39","author":"A Ciarmiello","year":"2012","unstructured":"Ciarmiello A, Giovacchini G, Orobello S, Bruselli L, Elifani F, Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. Eur J Nucl Med Mol Imaging. 2012;39(6):1030\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3445_CR18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996;11:136\u201342.","journal-title":"Mov Disord"},{"key":"3445_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.870100213","volume":"10","author":"A Feigin","year":"1995","unstructured":"Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, et al. Functional decline in Huntington\u2019s disease. Mov Disord. 1995;10:211\u20134.","journal-title":"Mov Disord"},{"issue":"9","key":"3445_CR20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RAC, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791\u2013801.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3445_CR21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet. 2004;65(4):267\u201377.","journal-title":"Clin Genet"},{"key":"3445_CR22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8:791\u2013801.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3445_CR23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00259-009-1264-0","volume":"36","author":"A Varrone","year":"2009","unstructured":"Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, N\u00e5gren K, et al. EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"3445_CR24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3233\/JAD-150814","volume":"49","author":"C Lange","year":"2015","unstructured":"Lange C, Suppa P, Frings L, Brenner W, Spies L, Buchert R. Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive impairment-to-Alzheimer\u2019s disease conversion. J Alzheimers Dis. 2015;49(4):945\u201359.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"3445_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroimage.2006.09.011","volume":"34","author":"R Casanova","year":"2007","unstructured":"Casanova R, Srikanth R, Baer A, Laurienti PJ, Burdette JH, Hayasaka S, et al. Biological parametric mapping: a statistical toolbox for multimodality brain image analysis. Neuroimage. 2007;34(1):137\u201343.","journal-title":"Neuroimage"},{"issue":"1","key":"3445_CR26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3988\/jcn.2013.9.1.21","volume":"9","author":"H Shin","year":"2013","unstructured":"Shin H, Kim MH, Lee SJ, Lee K-H, Kim M-J, Kim JS, et al. Decreased metabolism in the cerebral cortex in early-stage Huntington\u2019s disease: a possible biomarker of disease progression? J Clin Neurol. 2013;9(1):21\u20135.","journal-title":"J Clin Neurol"},{"issue":"11","key":"3445_CR27","first-page":"1591","volume":"42","author":"A Feigin","year":"2001","unstructured":"Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, et al. Metabolic network abnormalities in early Huntington\u2019s disease: an [18F]FDG PET study. J Nucl Med. 2001;42(11):1591\u20135.","journal-title":"J Nucl Med"},{"issue":"6","key":"3445_CR28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","volume":"43","author":"G Pagano","year":"2016","unstructured":"Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43(6):1171\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"3445_CR29","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","volume":"130","author":"A Feigin","year":"2007","unstructured":"Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington\u2019s disease. Brain. 2007;130(11):2858\u201367.","journal-title":"Brain"},{"issue":"12","key":"3445_CR30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archneur.1996.00550120105023","volume":"53","author":"EH Aylward","year":"1996","unstructured":"Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53(12):1293\u20136.","journal-title":"Arch Neurol"},{"issue":"2","key":"3445_CR31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.410430216","volume":"43","author":"A Antonini","year":"1998","unstructured":"Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington\u2019s disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998;43(2):253\u20135.","journal-title":"Ann Neurol"},{"issue":"8","key":"3445_CR32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5(8):731\u20136.","journal-title":"Nat Neurosci"},{"key":"3445_CR33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0166-2236(00)01584-8","volume":"23","author":"MF Beal","year":"2000","unstructured":"Beal MF. Energetics in the pathogenesis of neurodegenrative diseases. Trends Neurosci. 2000;23:298\u2013304.","journal-title":"Trends Neurosci"},{"issue":"7","key":"3445_CR34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-009-1103-3","volume":"36","author":"F Squitieri","year":"2009","unstructured":"Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging. 2009;36(7):1113\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3445_CR35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainresbull.2006.10.028","volume":"72","author":"EH Aylward","year":"2007","unstructured":"Aylward EH. Changes in MRI striatal volumes as a biomarker in preclinical Huntigton\u2019s disease. Brain Res Bull. 2007;72:152\u20138.","journal-title":"Brain Res Bull"},{"issue":"3\u20134","key":"3445_CR36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresbull.2010.04.003","volume":"82","author":"JS Paulsen","year":"2010","unstructured":"Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3\u20134):201\u20137.","journal-title":"Brain Res Bull"},{"issue":"3","key":"3445_CR37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P","volume":"15","author":"EH Aylward","year":"2000","unstructured":"Aylward EH, Codori AM, Rosenblatt A, Sherr M, Brandt J, Stine OC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington\u2019s disease. Mov Disord. 2000;15(3):552\u201360.","journal-title":"Mov Disord"},{"key":"3445_CR38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.410230603","volume":"23","author":"S Berent","year":"1988","unstructured":"Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, et al. Positron emission tomographic scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of cognitive function. Ann Neurol. 1988;23:541\u20136.","journal-title":"Ann Neurol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3445-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3445-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T08:44:36Z","timestamp":1568105076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3445-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3445-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]}}}